Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Hookipa Pharma Inc
(NQ:
HOOK
)
5.100
-0.110 (-2.11%)
Streaming Delayed Price
Updated: 12:14 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Hookipa Pharma Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
HOOKIPA Pharma Announces Board of Directors Changes
Today 8:00 EDT
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOK Stock Earnings: HOOKIPA Pharma Misses EPS, Misses Revenue for Q2 2024
August 09, 2024
HOOK stock results show that HOOKIPA Pharma missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via
InvestorPlace
HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 08, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200
July 22, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Why HOOKIPA Pharma (HOOK) Stock Is Volatile Today
July 08, 2024
HOOKIPA Pharma shares are trading lower by 10.9% during Monday's session. The company announced a 1-for-10 reverse stock split.
Via
Benzinga
Deep Dive Into HOOKIPA Pharma Stock: Analyst Perspectives (4 Ratings)
May 21, 2024
Via
Benzinga
HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split
July 08, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV
July 01, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Keurig Dr Pepper To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
June 05, 2024
Via
Benzinga
HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting
June 04, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Breaking Down HOOKIPA Pharma: 4 Analysts Share Their Views
April 26, 2024
Via
Benzinga
HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting
May 30, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
May 27, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
May 24, 2024
Via
Benzinga
HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting
May 23, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma: Q4 Earnings Insights
March 22, 2024
Via
Benzinga
Penny Stock Sleepers: 7 Under-the-Radar Gems Ready to Launch
May 16, 2024
Penny stocks to buy understandably offers many enticing attributes, not least of which is the potential for tremendous returns.
Via
InvestorPlace
HOOK Stock Earnings: HOOKIPA Pharma Beats EPS, Beats Revenue for Q1 2024
May 09, 2024
HOOK stock results show that HOOKIPA Pharma beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 09, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Stocks Creating Buzz Look Now: VTAK, AMST, HOOK, MULN, KAVL
April 26, 2024
Via
AB Newswire
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
April 25, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Why Is Penny Stock HOOKIPA Pharma Trading Higher On Wednesday?
April 24, 2024
HOOKIPA Pharma secures FDA clearance for its innovative HB-700 therapeutic vaccine targeting KRAS-mutated cancers. Learn about its broad impact on lung, colorectal, and pancreatic cancers, achieving...
Via
Benzinga
Exposures
Product Safety
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
April 24, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
April 16, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Roche's Lymphoma Drug With Chemo Extends Survival In Pretreated Patients
April 15, 2024
Roche study results show prolonged survival in R/R diffuse large B-cell lymphoma patients treated with Columvi (glofitamab) + GemOx vs. Rituxan + GemOx.
Via
Benzinga
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
April 10, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOK Stock Earnings: HOOKIPA Pharma Misses EPS, Beats Revenue for Q4 2023
March 22, 2024
HOOK stock results show that HOOKIPA Pharma missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
Via
InvestorPlace
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
March 22, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
March 06, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Roche Terminates Cancer Drug Pact With Repare Therapeutics, Its Second Walkout Within A Month
February 13, 2024
Repare Therapeutics regains global rights to camonsertib (RP-3500) after terminating collaboration with Roche. $40M milestone achieved.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.